Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured an Australian patent for two of its anti-infective drug candidates — the first in its Patent Family 4 cohort.
The Australian patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), specifically:
- how Recce prepares its anti-infectives;
- using R327 and R529 to treat diseases and bacterial and viral infections, further validating their use in studies covering burn wounds, urinary tract infections, gonorrhoea, influenza and SARSCoV2; and
- administering the anti-infectives via oral, inhalation or transdermal delivery methods, as well as via injection or through an aerosol, gel, topical foam or ointment.
Myriad bacteria and viral pathogens are covered in Recce’s Patent Family 4; a promising sign of R327 and R529’s extensive treatment opportunities.
R327 data validated
Thursday’s patent news comes just days after Recce verified some positive Phase 1 data from an R327 intravenous study.
Recently, the company conducted a randomised, placebo-controlled, first-in-human trial to evaluate how R327 performed as an intravenous infusion formulation in 80 healthy male subjects.
Since then, independent examiners have looked over data from the 80-person trial, finding all participants achieved the primary study end-points and met international regulatory data standards, indicating R327 is safe and well tolerated.
Overall, R327 was found to be well tolerated with a good safety profile across all dose groups from 50 milligrams to 6,000 milligrams when administrated intravenously over one-hour infusion.
Recce has since completed a Phase I/II UTI clinical trial ahead of schedule, evaluating R327 at faster intravenous infusion rates.
Graham explained: “R327 via two faster infusion rates of 2,500mg across male and female subjects continues to be shown as safe and well tolerated.
“Completing dosing well ahead of schedule is a welcomed confirmation that we are on track to achieving study objectives."